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Bladder cancer is the third most common malignancy in men in Sweden and a total of 2560 
patients were diagnosed with new disease in 2015. Over 95% of the tumours are of urothelial 
origin. Approximately 75% of the patients present with a non-muscle invasive bladder cancer 
(NMIBC). The first treatment is a transurethral resection of the bladder (TURB) and no further 
treatment is necessary for those with a non-invasive and low-grade tumour. A second resection 
is recommended for patients with high-grade tumours in order to verify that no muscle invasion 
is present. These patients require additional intravesical treatment with either chemotherapy or 
bacillus Calmette-Guérin (BCG) vaccine. Side-effects are common and often transient but late 
side-effects are rarely seen. The prognosis of NMIBC is generally good, but for high-grade 
tumours there is a higher progression rate. The recurrence rate is very high for NMIBC resulting 
in multiple TURBs with high costs. The aims of this thesis were to report a late BCG-
complication not previously described and to investigate the incidence of late recurrences in 
BCG-treated patients. Furthermore to register the number, size and histopathology of new and 
recurrent tumours and to register self-reported pain perception during transurethral procedures. 
In the first paper we describe a large lesion in the bladder with a persisting mycobacterial 
infection in 13 patients. The majority received tuberculostatic treatment and the lesions and 
infections disappeared. The second paper is a report on a large cohort of BCG-treated patients 
who had a tumour-free period of at least five years at some point after BCG-treatment. We 
found 10.8% late recurrences, suggesting that these patients require lifelong follow-up. The 
third study was a prospective registration of the size, number and histopathology of all new and 
recurrent bladder tumours during 15 months. The results showed that 22% in both groups were 
benign or inflammatory lesions and the absolute majority of recurrences were smaller than 10 
mm, which has not previously been demonstrated. The fourth paper consists of a prospective 
registration of 1572 patients with self-reported pain, experienced during cystoscopy and 
transurethral procedures under local anaesthesia. The pain levels at cystoscopy were generally 
low and in accordance with previous reports. At transurethral tumour extirpations the pain levels 
were higher than at cystoscopy only but still within an acceptable range. The two latter studies 
support the increased use of biopsies and fulguration under local anaesthesia as most 
recurrences are small and easily managed in the office setting.  
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